Live In Play®
Updated: 05-Jan-22 06:47 ET
PFE:  Pfizer and BioNTech (BNTX) sign new global collaboration agreement to develop first mRNA-based shingles vaccine   (54.53)
  • Clinical trials are expected to start in the second half of 2022
  • BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of $150 million, and will be eligible to receive future approval and sales milestone payments totaling up to $200 million as well as a share of gross profits arising from future product sales
  • Pfizer will receive an upfront payment of $25 million from BioNTech for its proprietary antigen sequences identified by Pfizer
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.